Comparing SG&A Expenses: Alkermes plc vs Veracyte, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding the financial dynamics of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Alkermes plc and Veracyte, Inc. over the past decade.

Alkermes plc: A Steady Climb

From 2014 to 2023, Alkermes plc has seen a consistent increase in SG&A expenses, growing by approximately 245%. This upward trend reflects the company's strategic investments in marketing and administrative functions, crucial for maintaining its competitive edge.

Veracyte, Inc.: Rapid Growth

Veracyte, Inc. presents a different narrative, with SG&A expenses skyrocketing by over 350% during the same period. This surge underscores the company's aggressive expansion and market penetration strategies, particularly evident in the significant jump between 2020 and 2021.

Conclusion

These trends highlight the contrasting growth strategies of Alkermes plc and Veracyte, Inc., offering valuable insights for investors and industry analysts.